A Research Study of VCT220 in Adult Chinese Participants With Obesity

StatusCompleted
PhasePhase 3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed
    • Eligibility criteria expanded, about 16 words
    • Secondary endpoints: details revised at 2 of 13 entries
    • Site details revised
  2. Primary completion date changed from estimate of Oct 25, 2025 to Nov 25, 2025
    • Study completion date: Mar 27, 2026 to Mar 31, 2026
    v2
  3. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The main purpose of this study is to assess how VCT220 tablets affect the bodyweight in obese or overweight adult participants. Participant will be randomly assigned to the high-dose group, low-dose group, or placebo group. Each participant will take the study drug orally once daily for 12 months.
Trial Details
NCT Number NCT06939296
Lead Sponsor Vincentage Pharma Co., Ltd
Conditions
(from sponsor)		 Obesity, Overweight
Related terms Obesity, Overweight
Enrollment 840 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov